Glenza 40mg Capsule contains Enzalutamide 40mg, an androgen receptor inhibitor used primarily in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide functions by competitively inhibiting androgen binding to androgen receptors, thereby preventing receptor translocation to the nucleus, DNA binding, and subsequent transcription of androgen-responsive genes that promote tumor growth. This mechanism effectively reduces cancer cell proliferation and progression in patients with advanced prostate cancer. Glenza is indicated for use in adult male patients with mCRPC who have previously undergone androgen deprivation therapy. The recommended dosage is one 40mg capsule daily, which may be adjusted based on clinical response and tolerability. Common adverse effects include fatigue, hypertension, hot flashes, and musculoskeletal pain, while serious but less frequent risks involve seizures and cardiovascular events. Patients should be monitored regularly for signs of adverse reactions and laboratory parameters. Glenza should be used cautiously in patients with a history of seizures or cardiovascular disease. It is contraindicated in patients with hypersensitivity to Enzalutamide or any capsule components. Glenza 40mg Capsule offers a targeted therapeutic option that improves progression-free survival and overall outcomes in advanced prostate cancer management when used as part of a comprehensive oncologic treatment plan.